| |
|
Institute for OneWorld Health— About Us: Our Team
Leading the effort against diseases
of poverty
Executive Team
Victoria Hale, Ph.D.
Founder and Chair of the Board of Directors
Ahvie Herskowitz, M.D.
Co-Founder, Chief Medical Officer and Senior Vice President Partnerships
David Brown, Ph.D., FRSC
Senior Advisor, Head of Drug Discovery
Julie Cheng
Vice President and General Counsel
Raj Shankar Ghosh
Country Director, India
Nina Grove, MA, MPH
Vice President, Commercialization Strategy & Planning, Senior Program Director, Malaria
James Hickman, MBA
Vice President, Communications and Fund Development
Tue Nguyen, Ph.D.
Vice President, Chemistry, Manufacturing and Controls (CMC)
Senior Staff
Cristina Cavani
Director, Human Resources
Philippe Desjeux, Ph.D., M.D.
Senior Program Officer of Disease Control
Barbara Hickingbottom, M.D., J.D.
Director, Clinical Development
Tasleem Kachra, MPH, MBA
Senior Director, Marketing and Logistics
Helen Matzger, MPH
Phase IV Program Director
Bao Nguyen
Senior Director, Information Technology
Lauren Thorner, Ph.D.
Director, Project Management,
Diarrheal Disease Program
Susan Wilson, Ph.D.
Senior Program Director,
Diarrheal Disease
Katherine Woo, Ph.D.
Senior Director, Corporate Partnering and Portfolio Development
|
|
Victoria Hale, Ph.D., Founder and Chair of the Board of Directors.
Dr. Hale established
her expertise in all stages of biopharmaceutical drug development at the
US Food and Drug Administration (FDA), Center for Drug Evaluation and
Research; and at Genentech, Inc., the world's first biotechnology company.
She presently maintains an Adjunct Associate Professorship in Biopharmaceutical
Sciences at the University of California, San Francisco (UCSF), is an
Advisor to the World Health Organization (WHO) for building ethical review
capacity in the developing world, and has served as an expert reviewer
to the National Institutes of Health (NIH) on the topic of biodiversity.
Dr. Hale’s recent honors include; being elected to membership in the Institute
of Medicine of the National Academies in 2007, being named a John D. and Catherine
T. MacArthur Foundation Fellow in 2006 and selection as an Ashoka Fellow
for work in leading social innovation also in 2006. In 2005, The Economist named
Hale the recipient of its Social and Economic Innovation award and Esquire Magazine named
her “Exec of the Year”. That same year OneWorld Health was awarded the Social
Responsibility Award at the prestigious Pharmaceutical Achievement Awards competition
and received the Skoll Award for Social Entrepreneurship. In 2004, Hale was named one the
Most Outstanding Social Entrepreneurs by the Schwab Foundation for Social Entrepreneurship.
Also in 2004, Dr. Hale and OneWorld Health were included in the Scientific American 50,
the magazine’s annual list recognizing outstanding acts of leadership in
science and technology.
 Ahvie Herskowitz, M.D.
Senior Vice President and Chief Medical Officer, Co-Founder provides senior executive leadership to the Institute for OneWorld Health. He has extensive experience performing large-scale multinational phase II and III clinical trials. Prior to co founding iOWH Ahvie directed all multinational clinical trials at a cardiovascular research institute, including all epidemiologic and outcome studies and registries. Dr. Herskowitz has been trained in the fields of cardiology, immunology and pathology. A former Associate Professor of Medicine, Immunology and Molecular Microbiology at Johns Hopkins, Dr. Herskowitz is a Clinical Professor in the Department of Medicine at University of California, San Francisco. He received his MD from Albert Einstein College of Medicine.
 David
Brown Ph.D., FRSC, Senior Advisor, Head of Drug Discovery, has
over 30 years experience in the pharmaceutical industry both in research
and in senior executive roles. He served with 4 of the top 10 Pharma companies:
Zeneca, Pfizer, Glaxo, and most recently with F. Hoffman La-Roche as Global
Head of Drug Discovery, Roche Pharma. In this role he had responsibility
for the output of clinical candidate drugs from approximately 2000 scientists
across Roche’s 5 research sites. Dr Brown has extensive experience
of pharmaceutical R&D in all phases from early discovery through clinical
trials, and he has experience of leading research in all major disease
areas. Whilst at Pfizer he was named co-inventor on the patent for Viagra,
and he led the team that developed Viagra through to proof of concept
(clinical efficacy) in man. At Roche, Dr Brown also served on the committee
responsible for clinical drug development and he was a core member of
the Business Development Committee responsible for in-licensing of products
and for technology agreements and acquisitions. Dr Brown received his
PhD in Chemistry from the University of Bristol. He is an Editor-in-Chief
of Current Opinion in Drug Discovery and Development, and is author of
more than 50 primary and review publications and patents.
Julie Cheng, Vice President and General Counsel,
oversees all iOWH legal matters. Her legal experience has primarily been
in the corporate world, including working at the FMC Corporation and Alcon
Laboratories Inc. Prior to joining OneWorld Health she spent almost seven
years with Bayer HealthCare with her most recent position being Assistant
General Counsel. Before that she worked in Philadelphia for Rohm and Haas
Company, where her focus was on international intellectual property.
Julie’s community activities have included participating on the
board of the Public Interest Law Center of Philadelphia (PILCOP) and
working with Big Brothers Big Sisters, Philadelphia Volunteer Lawyers for
the Arts, the West Texas Legal Services, and the AIDS Outreach Center. Julie
has been involved with the National Asian Pacific American Bar Association
(NAPABA) as well as local Asian Pacific American bar associations for several
years. Julie was also a member of the ABA Special Committee on Bioethics and
the Law from 2001 – 2004. Julie received her B.A. from Reed College and
her J.D. from Franklin Pierce Law Center.
 Raj Shankar Ghosh, Country Director, India is responsible for all operational and program services in the Liaison Field Office. He ensures that all programs are implemented with quality, accountability and measurable impact. Dr. Ghosh is also the iOWH representative in India. Dr. Ghosh has worked in the field of public health for the past 15 years. In recent years he has been directing the immunization work of PATH in India. There, he was responsible for the planning and implementation of the Japanese Encephalitis Project, the Cervical Cancer Vaccine project and other work related to primary immunization in the country. Prior to joining PATH in 2004 he worked in various parts of India particularly in the under developed districts as staff of State Health Services and the National Polio Surveillance Project of the WHO. Dr Ghosh completed his graduation in Medicine in 1988. During his career, he has obtained professional training from leading public health institutes in India including the Indian Institute of Health Management and Research and the Indian Institute of Public Health in India. Dr Ghosh has participated in generating several policy level decisions at the National and State level as member of several health committees including the National Technical Advisory Group on Immunization in India. He is an avid reader and loves to listen to music, particularly folk music.
 Nina Grove, M.A., M.P.H, is Vice President, Commercialization Strategy & Planning, Senior Program Director, Malaria. She brings over 20 years biopharmaceutical leadership and implementation experience in all aspects of drug development to OneWorld Health. During 20 years at Genentech, Inc., Nina held positions in Quality Control, Product Operations, Product Development, and most recently as Director of Commercial Regulatory Affairs where she was responsible for the product launch of four new drugs over a period of 24 months for asthma, cancer, and psoriasis. Prior to joining Genentech, Nina performed laboratory research both at the University of California, Berkeley, and at Stanford University. Nina earned her BA in Biology from the University of California at Santa Cruz and her Masters in Medical Microbiology and a Masters in Public Health from the University of California, Berkeley. Her professional affiliations include the Drug Information Association, Food and Drug Law Institute, and the Regulatory Affairs Professional Society.
 James Hickman, MBA, Vice
President, Communications and Fund Development, brings over twenty years of experience in strategic communications, advocacy
and fund development addressing health care access to the Institute for OneWorld Health. Most recently, he served as President and CEO
of the St. Luke’s Hospital Foundation, where he led fund development, community benefit and external relations programs for St. Luke’s
Hospital. Previously, Jim was the Bay Area Regional Director for Blue Cross of California State Sponsored Programs, a Wellpoint, Inc.
subsidiary, where he was responsible for its Medi-Cal and Healthy Families managed care programs. Prior to joining Blue Cross, Jim
worked at the U.S. Department of Health and Human Services during the Clinton Administration, first as staff to the White House Working
Group on Welfare Reform, and later as Special Assistant to the Office of Legislative Affairs. Jim has worked in politics at the
national, state and local levels for a diverse range of causes and clients providing event management, fundraising and voter contact
services.
 Tue Nguyen, Ph.D., Vice President, Chemistry, Manufacturing and Controls (CMC), is responsible for providing strategic technical and regulatory CMC expertise to the project teams. He directs and facilitates all CMC activities related to product evaluation and development, regulatory filing, product launch, and quality assurance. Tue has over twenty years of pharmaceutical development experience with all phases of small molecule and protein formulation / drug delivery device / parenteral manufacturing process development. He has held leadership positions in Pharmaceutical Research and Development, and in Analytic Sciences at Genentech. He is a fellow of the American Association of Pharmaceutical Scientists and a member of several other science organizations including AAAS and PDA. Tue received his Ph.D. in Pharmaceutical Chemistry from the University of Kansas.
Senior Staff
 Cristina Cavani, Director, Human Resources, has over 20 years of office management and administration experience. She has extensive knowledge of the banking industry and financial planning. She was a business entrepreneur in San Francisco for 8 years.
 Philippe Desjeux, Ph.D., M.D., Senior Program Officer of Disease Control. Dr. Desjeux brings more than three decades of experience in leishmaniasis surveillance, control and prevention to OneWorld Health, joining the team that is working to implement a paromomycin pre-launch program in Bihar, India. Dr. Desjeux previously worked as Leishmaniasis Research Coordinator for the Special Programme for Research and Training in Tropical Diseases of the World Health Organization (WHO/TDR). He received a medical doctorate from the University of Paris, and certificates in special studies—gastroenterology, parasitology, and systematic microbiology—from the Odeon Faculty of Medicine and the Pasteur Institute.
 Barbara Hickingbottom, M.D., J.D. Senior Director, Clinical Development. is responsible for designing the infrastructure and clinical team necessary to conduct Phase 1-4 clinical trials; for developing clinical trial protocols and strategies; and for overseeing safety monitoring. Prior to joining OneWorld Health as a full time employee Barbara worked as a consulting medical monitor for the iOWH VL team. She previously established a consulting practice that worked with numerous biotechnology companies engaged in international clinical development. Prior to her career in biotechnology, she practiced law. She earned her law degree (with honors) from Harvard Law School and her medical degree from Tufts University. Her post-graduate medical training was at Stanford.
 Tasleem Kachra, MPH, MBA, Senior Director, Marketing and Logistics, has five years of US pharmaceutical experience in marketing, project management, and market research at Roche Pharmaceuticals. She has also worked with various nonprofits in Kenya and Uganda; where she served as an internal consultant for the Aga Khan Hospital Nairobi, compiled and produced the 1996 edition of the Kenyan Pharmaceutical Index, and conducted an independent assessment of rural clinics in Masaka, Uganda. Tasleem received her M.P.H. and M.B.A. from Yale University.
 Helen Matzger, MPH, Phase IV Program Director is responsible for the overall tactical planning, coordinating and implementation of the Phase 4 activities for iOWH field research and the Phase 4 Program in India. Prior to joining OneWorld Health she spent eight years as a Research Investigator at UCSF working on domestic public health issues (alcohol and drug abuse). Helen has also worked on a variety of international public health issues including jobs with Helen Keller International (Dhaka, Bangladesh) and Indian NGO's while living in India. During her tenure in South Asia, she helped coordinate a unique nationwide health and nutritional surveillance system and was responsible for analyses on the health and nutritional status of women and children. Helen graduated from UC Berkeley and received her MPH in International Health from the University of Michigan.
 Bao Nguyen, Senior Director, Information Technology, is an expert in networking, client servers, web based system development and clinical trial data management. He has worked on the design and implementation of large scale clinical trials for over a decade, overseeing data management systems for epidemiological and clinical research studies at UC Berkeley’s School of Public Health and the National Environmental Public Health Tracking Network at the Centers for Disease Control.
 Lauren Thorner, Ph.D, Director, Project Management, Diarrheal Disease Program ,
is responsible for providing project management expertise to support multiple R&D projects and associated core and sub-teams of the DD program. Lauren has over 20 years of research and project management experience in the development of biologics, small molecules and drug delivery devices. Most recently, she served as the Global Project Manager at PDL BioPharma for an antibody therapeutic in Phase 2 clinical studies. Prior professional experience includes serving as Director, Product Development & Project Management at Intarcia Therapeutics, Inc. Lauren transitioned from managing a research laboratory to project management while at Bayer Corporation, where she led efforts to take several new biologics from discovery through pre-clinical development. She received her Ph.D. in Microbiology from the University of California, Davis and her BA in Bacteriology from the University of California, Berkeley.
 Susan Wilson, Ph.D., Senior Program Director, Diarrheal Disease, has over 20 years broad based biopharmaceutical drug development and program management experience encompassing biologics, vaccines and small molecules. Most recently, Dr Wilson served as Project Leader for a small molecule drug development project at Theravance Inc. leading efforts through successful IND and IMPD submissions to complete a comprehensive Non-clinical safety and Phase 1 clinical development program. Prior professional experience includes leading a next generation protein therapeutics Oncology project from discovery through to pre-clinical development at Chiron Corp and establishing translational immunology capabilities at the California State Dept. of Public Health, Dana-Farber Cancer Institute and Chiron Corporation to provide immunopharmacology support for numerous Phase I-III international clinical studies in Oncology and HIV. Dr Wilson received a Ph.D in Medical Microbiology and a M.Sc in Immunology from the University of London (UK) and she completed her B.Sc (Hons) degree in Pharmacology at the University of Leeds (UK).
 Katherine Woo, Ph.D., Senior Director, Corporate Partnering and Portfolio Development, evaluates drug leads and technologies submitted by universities and companies for potential partnership opportunities. She has more than ten years of experience in biomedical research and research management that spans the fields of development neuroscience, addiction, infectious diseases and entrepreneurship. Most recently, she developed an initiative to encourage public-private collaboration in the rapid translation of research into new HIV therapeutics. Dr. Woo received her Ph.D. from the California Institute of Technology, and Master’s and Bachelor’s degrees from Cornell University.
|
|
